Imugene Limited Profit Margin

The latest profit margin for IMU.AX is -3963.47% as of June 2026. That compares with -1120.18% in the prior-year period — down 253.8% year over year. That is below the Healthcare sector average of 10.58%. Investors often review this figure alongside Imugene Limited's historical trend and sector peers before judging valuation or financial health.

Over the past year, IMU.AX's profit margin moved from -1120.18% to -3963.47% — a 253.8% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Imugene Limited's valuation or profitability profile.

Against Healthcare companies, IMU.AX currently prints -3963.47% for profit margin, while the sector average sits near 10.58%. That is roughly 37560.3% below the sector mean. Large gaps often invite a closer look at Imugene Limited's growth, margins, and balance sheet.

Profit Margin shows how effectively Imugene Limited converts resources into returns. At -3963.47%, IMU.AX may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -1120.18% in the prior-year period — down 253.8% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting IMU.AX's profit margin (-3963.47%), review year-over-year change from -1120.18%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.